EVerMed (Drug Discovery) Overview
- Year Founded
-
2024
- Status
-
Private
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$3.25M
- Investors
-
4
EVerMed (Drug Discovery) General Information
Description
Operator of a biotechnology company intended to realize everlasting medical treatment through the therapeutic use of extracellular vesicles. The company focuses on the use of EVs, a natural homeostatic mechanism in the human body, and tries to create new treatments that address the root causes of diseases, enabling medical professionals to provide treatment for intractable respiratory diseases using extracellular vesicles.
Contact Information
Website
www.evermed.jpCorporate Office
- 3-25-8 Nishishinbashi
- Minato-ku
- Tokyo
- Japan
Corporate Office
- 3-25-8 Nishishinbashi
- Minato-ku
- Tokyo
- Japan
EVerMed (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 28-Jan-2025 | $3.25M | Completed | Startup |
EVerMed (Drug Discovery) Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Nissay Capital | Venture Capital | Minority | ||
| San-Ai Corporation | Corporation | Minority | ||
| Summit Pharmaceuticals International | Corporation | Minority | ||
| Waseda University Ventures | Venture Capital | Minority |
EVerMed (Drug Discovery) FAQs
-
When was EVerMed (Drug Discovery) founded?
EVerMed (Drug Discovery) was founded in 2024.
-
Where is EVerMed (Drug Discovery) headquartered?
EVerMed (Drug Discovery) is headquartered in Tokyo, Japan.
-
What industry is EVerMed (Drug Discovery) in?
EVerMed (Drug Discovery)’s primary industry is Drug Discovery.
-
Is EVerMed (Drug Discovery) a private or public company?
EVerMed (Drug Discovery) is a Private company.
-
What is EVerMed (Drug Discovery)’s current revenue?
The current revenue for EVerMed (Drug Discovery) is .
-
How much funding has EVerMed (Drug Discovery) raised over time?
EVerMed (Drug Discovery) has raised $3.25M.
-
Who are EVerMed (Drug Discovery)’s investors?
Nissay Capital, San-Ai Corporation, Summit Pharmaceuticals International, and Waseda University Ventures have invested in EVerMed (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process